GlassScriptPhysician profile
Kayla S Smith
NPI 1922611854
$2,344.73
in general payments reported to CMS, 2019-2025
15 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $434 · 2023: $493 · 2024: $808 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.66 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $592.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $318.73 | 2021-2025 | |
| Lilly USA, LLC | $285.35 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $137.85 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $135.64 | 2023-2024 | |
| Exact Sciences Corporation | $44.07 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $40.37 | 2025 | Otezla, Repatha |
| Virtus Pharmaceuticals LLC | $32.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.57 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $25.95 | 2025 | Givlaari |
| Medtronic, INC. | $19.80 | 2021 | |
| Kestra Medical Technology Services, INC. | $19.32 | 2025 | Assure Wcd |
| Ipsen Biopharmaceuticals, INC | $19.22 | 2023 | Tazverik |
| Sumitomo Pharma America, INC. | $19.01 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.